This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Elevation Oncology Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Tammy Furlong

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2yrs
Participación del CEO	0.02%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	2.8yrs

Actualizaciones recientes de la dirección

Recent updates

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Sep 25

CEO

Tammy Furlong (54 yo)

2yrs

Permanencia

Ms. Tammy Furlong, CPA, PMP., serves as its secretary and serves as Principal Financial and Accounting Officer and Chief Financial Officer since July 12, 2023 Elevation Oncology, Inc. She served as a Vice...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
R. Carruthers	Independent Director	4.2yrs	US$142.00k	0% $ 0
Steven Elms	Independent Chairman of the Board	6.2yrs	US$169.07k	0% $ 0
Timothy Clackson	Independent Director	5.2yrs	US$139.09k	0.080% $ 17.3k
Julie Michele Cherrington	Independent Director	1.4yrs	US$288.79k	0% $ 0
Alan Bart Sandler	Independent Director	1.4yrs	US$285.10k	0% $ 0
Darcy Mootz	Independent Director	1.5yrs	US$230.90k	0% $ 0

2.8yrs

Permanencia media

64.5yo

Promedio de edad

Junta con experiencia: La junta directiva de ELEV no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2025/07/24 15:59
Precio de las acciones al final del día	2025/07/22 00:00
Beneficios	2025/03/31
Ingresos anuales	2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Elevation Oncology, Inc. está cubierta por 4 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Silvan Tuerkcan	Citizens JMP Securities, LLC
Swayampakula Ramakanth	H.C. Wainwright & Co.
Michael King	H.C. Wainwright & Co.

This company has been acquired

Elevation Oncology Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Elevation Oncology, Inc., Annual General Meeting, Jun 05, 2025

Elevation Oncology, Inc., Annual General Meeting, Jun 13, 2024

Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee

Elevation Oncology, Inc Appoints Joseph J. Ferra, Jr. as Chief Executive Officer

Advisor notifies of intention to sell stock

Recent updates

Elevation Oncology, Inc.(NasdaqCM:ELEV) dropped from NASDAQ Composite Index

Concentra Biosciences, LLC completed the acquisition of 67.09% of Elevation Oncology, Inc. (NasdaqCM:ELEV).

Concentra Biosciences, LLC entered into a definitive merger agreement to acquire Elevation Oncology, Inc. (NasdaqCM:ELEV) for $21.4 million.

Elevation Oncology Presents Preclinical Proof-Of-Concept Data for EO-1022 At the American Association for Cancer Research Annual Meeting 2025

BML Capital Management Sends a Letter to the Board of Elevation Oncology

Elevation Oncology, Inc., Annual General Meeting, Jun 05, 2025

Nasdaq Approves Elevation Oncology’s Request to Transfer Listing of Common Stock from Nasdaq Global to Nasdaq Capital Market

Elevation Oncology, Inc. Implements A Workforce Reduction of Approximately 70%

New major risk - Financial position

New major risk - Shareholder dilution

Elevation Oncology Advances EO-3021 and EO-1022 ADC Programs with Promising Phase 1 Data and Upcoming Milestones

New major risk - Revenue and earnings growth

Elevation Oncology, Inc. Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-Expressing Solid Tumors

Elevation Oncology, Inc. Presents Preclinical Proof-Of-Concept Data Supporting Combination Potential of Eo-3021 with Vegfr2 or Pd-1 Inhibitors At Esmo Immuno-Oncology Annual Congress 2024

Price target decreased by 8.2% to US$7.50

Elevation Oncology Receives Non-Compliance Letter Regarding Nasdaq Minimum Bid Price Requirement

New minor risk - Market cap size

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

Elevation Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Elevation Oncology, Inc., Annual General Meeting, Jun 13, 2024

Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee

Elevation Oncology: Rising On News, But Not The Time To Buy

Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021

New minor risk - Share price stability

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021

Elevation Oncology, Inc Appoints Joseph J. Ferra, Jr. as Chief Executive Officer

New major risk - Financial position

New major risk - Shareholder dilution

Elevation Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $50.062056 million.

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Price target increased by 24% to US$6.00

Advisor notifies of intention to sell stock

Advisor notifies of intention to sell stock

Price target decreased by 19% to US$4.17

Elevation Oncology, Inc. Announces Management Changes

Price target decreased to US$5.17

Elevation Oncology GAAP EPS of -$0.86 misses by $0.07

Elevation Oncology secured $50M loan facility with K2 HealthVentures

Now 36% undervalued after recent price drop

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022

We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely

Elevation Oncology, Inc. Appoints David Dornan as Chief Scientific Officer

Elevation Oncology, Inc., Annual General Meeting, Jun 17, 2022

Elevation Oncology, Inc. Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022

Less than half of directors are independent

We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Elevation Oncology, Inc. has completed an IPO in the amount of $100 million.

CEO

Miembros de la Junta

Análisis de la empresa y estado de los datos financieros

Fuentes de datos

Modelo de análisis y copo de nieve

Métricas industriales y sectoriales

Fuentes analistas